tiprankstipranks
AstraZeneca initiated with an Outperform at BMO Capital
The Fly

AstraZeneca initiated with an Outperform at BMO Capital

BMO Capital analyst Etzer Darout initiated coverage of AstraZeneca with an Outperform rating and $82 price target. AstraZeneca is a leader in pharmaceutical drug development, "buoyed by its diverse portfolio" of products in oncology, rare disease, and biopharmaceutical segments, Darout tells investors in a research note. The analyst says the company’s growth and margin expansion are undervalued relative to peers as it continues to migrate to higher-margin programs.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on AZN:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles